Table 1 Characteristics of the patients at baseline
Characteristic | Primary analysis set | Intention-to-treat analysis set | ||
|---|---|---|---|---|
Chemo-free (n = 9, %) | Chemo (n = 38, %) | Chemo-free (n = 21, %) | Chemo (n = 79, %) | |
Age, years, mean ± SD a | 63.78 ± 6.78 | 61.50 ± 7.99 | 61.90 ± 9.92 | 63.14 ± 8.57 |
Sex | ||||
Male | 9 (100.0) | 34 (89.5) | 19 (90.5) | 74 (93.7) |
Female | 0 (0.0) | 4 (10.5) | 2 (9.5) | 5 (6.3) |
ECOG performance status | ||||
0 | 9 (100.0) | 27 (71.1) | 18 (85.7) | 58 (73.4) |
1 | 0 (0.0) | 11 (28.9) | 3 (14.3) | 21 (26.6) |
PD-L1 expression level | ||||
≥ 50% | 3 (33.3) | 0 (0.0) | 8 (38.1) | 0 (0.0) |
1% ~ 50% | 6 (66.7) | 6 (15.8) | 13 (61.9) | 11 (13.9) |
<1% | 0 (0.0) | 13 (34.2) | 0 (0.0) | 21 (26.6) |
Unknown | 0 (0.0) | 19 (50.0) | 0 (0.0) | 47 (59.5) |
Smoking status | ||||
Never | 1 (11.1) | 4 (10.5) | 3 (14.3) | 7 (8.9) |
Current | 3 (33.3) | 26 (68.4) | 11 (52.3) | 54 (68.4) |
Former (≥1 y) | 5 (55.6) | 8 (21.1) | 7 (33.3) | 18 (22.8) |
Pack-years, median [IQR] a | 40.0 [23.8, 52.5] | 30.0 [20.0, 48.8] | 43.8 [23.1, 60.0] | 36.0 [21.9, 50.0] |
MTD at diagnosis, mm, median [IQR] | 29.0 [25.0, 50.0] | 43.0 [31.8, 61.3] | 43.0 [32.0, 56.0] | 47.0 [38.0, 68.5] |
N stage at diagnosis | ||||
N0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (3.8) |
N1 | 2 (22.2) | 3 (7.9) | 3 (14.3) | 13 (16.5) |
N2 | 5 (55.6) | 30 (78.9) | 12 (57.1) | 54 (68.4) |
N3 | 2 (22.2) | 5 (13.2) | 6 (28.6) | 9 (11.4) |
cTNM stage at diagnosis | ||||
IIIA | 4 (44.4) | 20 (52.6) | 5 (23.8) | 39 (49.4) |
IIIB | 4 (44.4) | 14 (36.8) | 14 (66.7) | 34 (43.0) |
IIIC | 1 (11.1) | 4 (10.5) | 2 (9.5) | 6 (7.6) |
Histologic features | ||||
Non-LUSCa | 2 (22.2) | 20 (52.6) | 6 (28.6) | 40 (50.6) |
LUSC | 7 (77.8) | 18 (47.4) | 15 (71.4) | 39 (49.4) |
